NCT05650333View on ClinicalTrials.gov

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions
Alopecia Areata
Interventions
DRUG

Ritlecitinib 20 mg

orally administered, Ritlecitinib 20 mg once daily (QD)

Trial Locations (9)

33146

Pediatric Skin Research,LLC, Coral Gables

33155

Nicklaus Children's Hospital, Miami

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

74136

Vital Prospects Clinical Research Institute, PC, Tulsa

78218

Texas Dermatology and Laser Specialists, San Antonio

87102

University of New Mexico Health Sciences Center, Albuquerque

87106

UNMH, Albuquerque

92024

California Dermatology & Clinical Research Institute, Encinitas

97210

Northwest Dermatology Institute, Portland

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05650333 - A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age | Biotech Hunter | Biotech Hunter